Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PTEN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PTEN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTEN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTEN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PTEN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTEN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTEN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTEN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTEN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200005812 | Liver | Cirrhotic | regulation of ubiquitin-dependent protein catabolic process | 81/4634 | 164/18723 | 7.22e-12 | 4.92e-10 | 81 |
GO:004428211 | Liver | Cirrhotic | small molecule catabolic process | 151/4634 | 376/18723 | 2.20e-11 | 1.34e-09 | 151 |
GO:001003812 | Liver | Cirrhotic | response to metal ion | 150/4634 | 373/18723 | 2.27e-11 | 1.37e-09 | 150 |
GO:190332012 | Liver | Cirrhotic | regulation of protein modification by small protein conjugation or removal | 105/4634 | 242/18723 | 1.43e-10 | 7.43e-09 | 105 |
GO:000606612 | Liver | Cirrhotic | alcohol metabolic process | 141/4634 | 353/18723 | 1.57e-10 | 8.03e-09 | 141 |
GO:009719112 | Liver | Cirrhotic | extrinsic apoptotic signaling pathway | 97/4634 | 219/18723 | 1.82e-10 | 9.11e-09 | 97 |
GO:200123612 | Liver | Cirrhotic | regulation of extrinsic apoptotic signaling pathway | 72/4634 | 151/18723 | 7.80e-10 | 3.62e-08 | 72 |
GO:003166712 | Liver | Cirrhotic | response to nutrient levels | 174/4634 | 474/18723 | 3.08e-09 | 1.27e-07 | 174 |
GO:190305211 | Liver | Cirrhotic | positive regulation of proteolysis involved in cellular protein catabolic process | 64/4634 | 133/18723 | 4.23e-09 | 1.70e-07 | 64 |
GO:003139612 | Liver | Cirrhotic | regulation of protein ubiquitination | 89/4634 | 210/18723 | 1.40e-08 | 5.30e-07 | 89 |
GO:015011512 | Liver | Cirrhotic | cell-substrate junction organization | 51/4634 | 101/18723 | 2.08e-08 | 7.47e-07 | 51 |
GO:200123512 | Liver | Cirrhotic | positive regulation of apoptotic signaling pathway | 60/4634 | 126/18723 | 2.08e-08 | 7.47e-07 | 60 |
GO:004206012 | Liver | Cirrhotic | wound healing | 155/4634 | 422/18723 | 2.12e-08 | 7.56e-07 | 155 |
GO:000974312 | Liver | Cirrhotic | response to carbohydrate | 101/4634 | 253/18723 | 6.24e-08 | 1.92e-06 | 101 |
GO:000941012 | Liver | Cirrhotic | response to xenobiotic stimulus | 165/4634 | 462/18723 | 6.82e-08 | 2.09e-06 | 165 |
GO:200006012 | Liver | Cirrhotic | positive regulation of ubiquitin-dependent protein catabolic process | 52/4634 | 107/18723 | 7.75e-08 | 2.30e-06 | 52 |
GO:004343412 | Liver | Cirrhotic | response to peptide hormone | 149/4634 | 414/18723 | 1.70e-07 | 4.49e-06 | 149 |
GO:015011612 | Liver | Cirrhotic | regulation of cell-substrate junction organization | 38/4634 | 71/18723 | 1.84e-07 | 4.82e-06 | 38 |
GO:003428412 | Liver | Cirrhotic | response to monosaccharide | 90/4634 | 225/18723 | 2.87e-07 | 7.01e-06 | 90 |
GO:007137511 | Liver | Cirrhotic | cellular response to peptide hormone stimulus | 110/4634 | 290/18723 | 3.73e-07 | 8.82e-06 | 110 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.404T>A | p.Ile135Lys | p.I135K | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389G>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | | c.593N>A | p.Met198Lys | p.M198K | P60484 | protein_coding | deleterious(0) | benign(0.285) | TCGA-AC-A2FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PTEN | SNV | Missense_Mutation | | c.384N>C | p.Lys128Asn | p.K128N | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.28N>C | p.Ser10Arg | p.S10R | P60484 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | rs786201995 | c.70G>A | p.Asp24Asn | p.D24N | P60484 | protein_coding | deleterious(0) | benign(0.012) | TCGA-AR-A1AM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PTEN | SNV | Missense_Mutation | | c.367C>G | p.His123Asp | p.H123D | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTEN | SNV | Missense_Mutation | | c.370N>A | p.Cys124Ser | p.C124S | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PI3KBETA INHIBITOR AZD8186 | | 25544636 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | TEMSIROLIMUS | TEMSIROLIMUS | 11504908,23674493 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Temsirolimus | TEMSIROLIMUS | 27016228 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PF-04691502 | PF-04691502 | 21750219 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PANITUMUMAB | PANITUMUMAB | 19223544 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Oxaliplatin | OXALIPLATIN | 24100628 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | DETD-35 | | 27048951 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | cisplatin | CISPLATIN | |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Copanlisib | COPANLISIB | 27672108 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Fulvestrant | FULVESTRANT | 26733612 |